563 related articles for article (PubMed ID: 22878500)
1. Loss of the tumor suppressor BAP1 causes myeloid transformation.
Dey A; Seshasayee D; Noubade R; French DM; Liu J; Chaurushiya MS; Kirkpatrick DS; Pham VC; Lill JR; Bakalarski CE; Wu J; Phu L; Katavolos P; LaFave LM; Abdel-Wahab O; Modrusan Z; Seshagiri S; Dong K; Lin Z; Balazs M; Suriben R; Newton K; Hymowitz S; Garcia-Manero G; Martin F; Levine RL; Dixit VM
Science; 2012 Sep; 337(6101):1541-6. PubMed ID: 22878500
[TBL] [Abstract][Full Text] [Related]
2. Cancer. Emerging anatomy of the BAP1 tumor suppressor system.
White AE; Harper JW
Science; 2012 Sep; 337(6101):1463-4. PubMed ID: 22997315
[No Abstract] [Full Text] [Related]
3. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
4. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression.
Yu H; Mashtalir N; Daou S; Hammond-Martel I; Ross J; Sui G; Hart GW; Rauscher FJ; Drobetsky E; Milot E; Shi Y; Affar el B
Mol Cell Biol; 2010 Nov; 30(21):5071-85. PubMed ID: 20805357
[TBL] [Abstract][Full Text] [Related]
5. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.
Daou S; Hammond-Martel I; Mashtalir N; Barbour H; Gagnon J; Iannantuono NV; Nkwe NS; Motorina A; Pak H; Yu H; Wurtele H; Milot E; Mallette FA; Carbone M; Affar el B
J Biol Chem; 2015 Nov; 290(48):28643-63. PubMed ID: 26416890
[TBL] [Abstract][Full Text] [Related]
6. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
[TBL] [Abstract][Full Text] [Related]
8. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
[TBL] [Abstract][Full Text] [Related]
9. Familial and Somatic
Peng H; Prokop J; Karar J; Park K; Cao L; Harbour JW; Bowcock AM; Malkowicz SB; Cheung M; Testa JR; Rauscher FJ
Cancer Res; 2018 Mar; 78(5):1200-1213. PubMed ID: 29284740
[TBL] [Abstract][Full Text] [Related]
10. Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.
Peng H; Cassel J; McCracken DS; Prokop JW; Sementino E; Cheung M; Collop PR; Polo A; Joshi S; Mandell JP; Ayyanathan K; Hinds D; Malkowicz SB; Harbour JW; Bowcock AM; Salvino J; Kennedy EJ; Testa JR; Rauscher FJ
Mol Cancer Res; 2021 Jul; 19(7):1099-1112. PubMed ID: 33731362
[TBL] [Abstract][Full Text] [Related]
11. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
[TBL] [Abstract][Full Text] [Related]
13. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
14. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
[TBL] [Abstract][Full Text] [Related]
15. An emerging model for BAP1's role in regulating cell cycle progression.
Eletr ZM; Wilkinson KD
Cell Biochem Biophys; 2011 Jun; 60(1-2):3-11. PubMed ID: 21484256
[TBL] [Abstract][Full Text] [Related]
16. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
Abdel-Wahab O; Dey A
Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.
Hurtado AM; Luengo-Gil G; Chen-Liang TH; Amaral F; Batta K; Palomo L; Lumbreras E; Przychodzen B; Caparros E; Amigo ML; Dıez-Campelo M; Zamora L; Salido Fierrez EJ; Maciejewski JP; Ortuño FJ; Vicente V; Del Canizo M; Sole F; Ferrer-Marin F; Wiseman DH; Jerez A
Br J Haematol; 2018 Aug; 182(3):373-383. PubMed ID: 29797327
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
Carr RM; Patnaik MM
Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
20. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]